Trade Coherus BioSciences - CHRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.98 |
| Open | 0.98 |
| 1-Year Change | -51.24% |
| Day's Range | 0.97 - 1.02 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.98 | -0.09 | -8.41% | 1.07 | 1.08 | 0.98 |
| Apr 23, 2025 | 1.08 | -0.01 | -0.92% | 1.09 | 1.13 | 1.08 |
| Apr 22, 2025 | 1.06 | 0.01 | 0.95% | 1.05 | 1.07 | 1.01 |
| Apr 21, 2025 | 1.03 | -0.04 | -3.74% | 1.07 | 1.08 | 1.00 |
| Apr 17, 2025 | 1.09 | 0.09 | 9.00% | 1.00 | 1.11 | 0.99 |
| Apr 16, 2025 | 0.98 | -0.03 | -2.97% | 1.01 | 1.04 | 0.96 |
| Apr 15, 2025 | 1.03 | 0.06 | 6.19% | 0.97 | 1.04 | 0.96 |
| Apr 14, 2025 | 0.95 | 0.08 | 9.20% | 0.87 | 0.96 | 0.84 |
| Apr 11, 2025 | 0.81 | 0.07 | 9.46% | 0.74 | 0.81 | 0.73 |
| Apr 10, 2025 | 0.72 | -0.04 | -5.26% | 0.76 | 0.78 | 0.71 |
| Apr 9, 2025 | 0.77 | 0.04 | 5.48% | 0.73 | 0.82 | 0.70 |
| Apr 8, 2025 | 0.75 | -0.08 | -9.64% | 0.83 | 0.85 | 0.73 |
| Apr 7, 2025 | 0.79 | 0.06 | 8.22% | 0.73 | 0.87 | 0.73 |
| Apr 4, 2025 | 0.75 | -0.02 | -2.60% | 0.77 | 0.79 | 0.73 |
| Apr 3, 2025 | 0.80 | -0.01 | -1.23% | 0.81 | 0.82 | 0.79 |
| Apr 2, 2025 | 0.89 | 0.12 | 15.58% | 0.77 | 0.89 | 0.76 |
| Apr 1, 2025 | 0.78 | -0.01 | -1.27% | 0.79 | 0.83 | 0.77 |
| Mar 31, 2025 | 0.78 | -0.02 | -2.50% | 0.80 | 0.81 | 0.77 |
| Mar 28, 2025 | 0.82 | -0.01 | -1.20% | 0.83 | 0.86 | 0.81 |
| Mar 27, 2025 | 0.82 | -0.07 | -7.87% | 0.89 | 0.89 | 0.81 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Coherus Biosciences Inc revenues decreased 31% to $326.6M. Net loss totaled $287.1M vs. income of $132.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development increase from $128.9M to $344.4M (expense), General and administrative increase of 20% to $138.1M (expense).
| Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com